KEITH A BAGGERLY to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications KEITH A BAGGERLY has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.294
-
Microarrays: retracing steps. Nat Med. 2007 Nov; 13(11):1276-7; author reply 1277-8.
Score: 0.065
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
Score: 0.036
-
High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017 09; 102(9):1537-1548.
Score: 0.032
-
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14.
Score: 0.027
-
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65.
Score: 0.025
-
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
Score: 0.024
-
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
Score: 0.021
-
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010 Jan 15; 16(2):711-8.
Score: 0.019
-
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat. 2010 Jun; 121(2):301-9.
Score: 0.018
-
Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer. 2004 May 01; 100(9):1814-22.
Score: 0.013
-
Independent validation of a model using cell line chemosensitivity to predict response to therapy. J Natl Cancer Inst. 2013 Sep 04; 105(17):1284-91.
Score: 0.006
-
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. Blood. 2012 Sep 27; 120(13):2679-89.
Score: 0.006